Survival Rate of Patients with Acute Leukemia: A Case Study in Iran

Evidence Based Health Policy, Management and Economics Pub Date : 2020-12-15 DOI:10.18502/jebhpme.v4i4.4888

M. Ranjbar, M. Barouni, V. Moazed, H. Fallahzadeh, S. Sheikholeslami

{"title":"Survival Rate of Patients with Acute Leukemia: A Case Study in Iran","authors":"M. Ranjbar, M. Barouni, V. Moazed, H. Fallahzadeh, S. Sheikholeslami","doi":"10.18502/jebhpme.v4i4.4888","DOIUrl":null,"url":null,"abstract":"Background: Acute leukemia is a kind of aggressive disease that includes high rates of fatalities in the world, in particular in Iran. This research was done to determine the survival rate of patients with acute leukemia in Iran. \nMethods: 85 adult patients who were first diagnosed with acute leukemia in Shahid Bahonar hospital of Kerman during March 2012 until March 2013 were evaluated in a retrospective descriptive study to measure the death/life status in a 5-year period (2012-2017). The required data was gathered from medical records of patients, HIS system data, and the cancer registry system, and the Kaplan-Meier estimator and Log Rank test were used to calculate the survival rate using SPSS23. \nResults: Survival rate was completely 45.9 % for patients with acute adult leukemia. It was 47.08 % in acute myelogenous leukemia (AML) and it was 43.06 % in acute lymphocytic leukemia (ALL). The 1,2,3,4 and 5-year survival of acute leukemia was respectively 87.1 %, 69.4 %, 62.4 %, 56.5 % and 45.9 %. \nConclusion: Iran's health system should design and plan to increase the survival of patients with acute leukemia by improving the methods and facilities to diagnose and treat it more quickly and more effectively.","PeriodicalId":198049,"journal":{"name":"Evidence Based Health Policy, Management and Economics","volume":"30 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence Based Health Policy, Management and Economics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/jebhpme.v4i4.4888","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Acute leukemia is a kind of aggressive disease that includes high rates of fatalities in the world, in particular in Iran. This research was done to determine the survival rate of patients with acute leukemia in Iran. Methods: 85 adult patients who were first diagnosed with acute leukemia in Shahid Bahonar hospital of Kerman during March 2012 until March 2013 were evaluated in a retrospective descriptive study to measure the death/life status in a 5-year period (2012-2017). The required data was gathered from medical records of patients, HIS system data, and the cancer registry system, and the Kaplan-Meier estimator and Log Rank test were used to calculate the survival rate using SPSS23. Results: Survival rate was completely 45.9 % for patients with acute adult leukemia. It was 47.08 % in acute myelogenous leukemia (AML) and it was 43.06 % in acute lymphocytic leukemia (ALL). The 1,2,3,4 and 5-year survival of acute leukemia was respectively 87.1 %, 69.4 %, 62.4 %, 56.5 % and 45.9 %. Conclusion: Iran's health system should design and plan to increase the survival of patients with acute leukemia by improving the methods and facilities to diagnose and treat it more quickly and more effectively.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

伊朗急性白血病患者的生存率

背景:急性白血病是一种侵袭性疾病，在世界范围内具有很高的死亡率，特别是在伊朗。这项研究是为了确定伊朗急性白血病患者的生存率。方法:对2012年3月至2013年3月在克尔曼Shahid Bahonar医院首次诊断为急性白血病的85例成年患者进行回顾性描述性研究，测量其2012-2017年5年期间的死亡/生活状况。从患者病历、HIS系统数据和癌症登记系统中收集所需数据，采用Kaplan-Meier估计和Log Rank检验，使用SPSS23计算生存率。结果:急性成人白血病患者的生存率为45.9%。急性髓性白血病(AML)为47.08%，急性淋巴细胞白血病(ALL)为43.06%。急性白血病患者1、2、3、4、5年生存率分别为87.1%、69.4%、62.4%、56.5%、45.9%。结论:伊朗的卫生系统应设计和计划通过改进方法和设施来更快、更有效地诊断和治疗急性白血病，从而提高急性白血病患者的生存率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Evidence Based Health Policy, Management and Economics

自引率

0.00%

发文量